-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – OTA-201 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - OTA-201 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. OTA-201 in Solid Tumor Drug Details: OTA-201 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BP-1002 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BP-1002 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BP-1002 in Relapsed Acute Myeloid Leukemia Drug Details: BP-1002...
-
Product Insights
NewCardiac Valve Repair Devices Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Cardiac Valve Repair Devices Pipeline Market Report Overview Cardiac valve repair devices are used in Open-Heart surgery to repair the malfunctioning of valves. Only mitral valve repair has been covered under this segment. Annuloplasty is a technique used to repair an enlarged annulus. This annuloplasty device makes the opening of the valve smaller and provides support to the valve so it can close more tightly. One unit refers to One cardiac valve repair device. The Cardiac Valve Repair Devices pipeline...
-
Product Insights
NewNet Present Value Model: Novartis AG’s Batoprotafib
Empower your strategies with our Net Present Value Model: Novartis AG's Batoprotafib report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Harpoon Therapeutics Inc’s HPN-217
Empower your strategies with our Net Present Value Model: Harpoon Therapeutics Inc's HPN-217 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Harpoon Therapeutics Inc’s HPN-328
Empower your strategies with our Net Present Value Model: Harpoon Therapeutics Inc's HPN-328 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Odronextamab in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Odronextamab in Mantle Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Odronextamab in Mantle Cell Lymphoma Drug Details: Odronextamab is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Darigabat in Panic Disorders
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Darigabat in Panic Disorders report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Darigabat in Panic Disorders Drug Details: Darigabat (CVL-865) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HPN-328 in Prostate Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HPN-328 in Prostate Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HPN-328 in Prostate Cancer Drug Details: HPN-328 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – HPN-328 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HPN-328 in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. HPN-328 in Colorectal Cancer Drug Details: HPN-328 is under development for the...